Michael Pinkawa
Overview
Explore the profile of Michael Pinkawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
127
Citations
1725
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wilke T, Hussain E, Spallek H, Terlizzi F, Mir L, Bischoff P, et al.
Radiol Oncol
. 2025 Feb;
59(1):100-109.
PMID: 40014781
Background: Electrochemotherapy (ECT) is a local nonsurgical effective tumor treatment in the hand of the clinician for the treatment of patients with liver tumors or metastases. The study aimed to...
2.
Pinkawa M, Bostrom J, Temming S, Schafer A, Kovacs A, Bostrom A
Strahlenther Onkol
. 2024 Jun;
201(2):191-196.
PMID: 38871938
Purpose: Abscopal effects have been reported predominantly in metastatic cancers, indicating a radiographic response in a lesion that has not been included in the radiotherapy target volume. The response is...
3.
Seymour Z, Pinkawa M, Daignault-Newton S, Bosch W, Michalski J, Gay H, et al.
Front Oncol
. 2023 Oct;
13:1239104.
PMID: 37886176
Purpose: The purpose of this study was to analyze the impact of prostate rectal spacers on sexual quality of life (QOL) following external beam radiation therapy (RT). Methods And Materials:...
4.
Pinkawa M, Haddad H, Schlenter M, Hermani H, Ho H, Kovacs A, et al.
Pract Radiat Oncol
. 2023 Oct;
14(1):57-64.
PMID: 37791943
Purpose: The aim of this study was to evaluate the application of a radiopaque viscous spacer (RVS) for prostate cancer radiation therapy (RT), including injection procedure, toxicity, treatment planning, image...
5.
Pinkawa M
Cancers (Basel)
. 2023 Sep;
15(17).
PMID: 37686572
Gastrointestinal toxicity, particularly in relation to rectal bleeding, is regarded as the dose-limiting toxicity in radiotherapy for prostate cancer, and it is the most frequent focus of toxicity studies [...].
6.
Bamias A, Stenzl A, Brown S, Albiges L, Babjuk M, Birtle A, et al.
Eur Urol
. 2023 May;
84(4):381-389.
PMID: 37217391
Background: In contrast to other cancers, the concept of oligometastatic disease (OMD) has not been investigated in bladder cancer (BC). Objective: To develop an acceptable definition, classification, and staging recommendations...
7.
Haddad H, Hermani H, Hanitzsch H, Heidrich A, Pinkawa M
Cancers (Basel)
. 2023 Mar;
15(5).
PMID: 36900188
The study aimed to compare the dose distribution in permanent low-dose-rate brachytherapy (LDR-BT) and high-dose-rate brachytherapy (HDR-BT), specifically focusing on the impact of a spacer and prostate volume. The relative...
8.
Spohn S, Draulans C, Kishan A, Spratt D, Ross A, Maurer T, et al.
Int J Radiat Oncol Biol Phys
. 2023 Jan;
116(3):503-520.
PMID: 36596346
Current risk-stratification systems for prostate cancer (PCa) do not sufficiently reflect the disease heterogeneity. Genomic classifiers (GC) enable improved risk stratification after surgery, but less data exist for patients treated...
9.
Pinkawa M, Hermani H, Bischoff P, Hanitzsch H, Heidrich A, Schafer A, et al.
Brachytherapy
. 2022 Sep;
21(6):848-852.
PMID: 36055928
Purpose: Close vicinity of the target volume and a sensitive organ may prevent an effective radiotherapy/brachytherapy. A liquid hydrogel spacer cannot be placed well focally in specific small areas or...
10.
Radiotherapy for hormone-sensitive prostate cancer with synchronous low burden of distant metastases
Muller A, Aebersold D, Albrecht C, Bohmer D, Flentje M, Ganswindt U, et al.
Strahlenther Onkol
. 2022 Jun;
198(8):683-689.
PMID: 35704054
Purpose: The DEGRO Expert Commission on Prostate Cancer has revised the indication for radiation therapy of the primary prostate tumor in patients with synchronous distant metastases with low metastatic burden....